The latest price target for Small Pharma Inc (OTC:DMTTF) was reported by HC Wainwright & Co. on February 7, 2023. The analyst firm set a price target for $2.50 expecting DMTTF to rise to within 12 months (a possible 2138.14% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Small Pharma Inc (OTC:DMTTF) was provided by HC Wainwright & Co., and Small Pharma Inc reiterated their buy rating.

There is no last upgrade for Small Pharma Inc

There is no last downgrade for Small Pharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Small Pharma Inc, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Small Pharma Inc was filed on February 7, 2023 so you should expect the next rating to be made available sometime around February 7, 2024.

While ratings are subjective and will change, the latest Small Pharma Inc (DMTTF) rating was a reiterated with a price target of $0.00 to $2.50. The current price Small Pharma Inc (DMTTF) is trading at is $0.11, which is within the analyst’s predicted range.